D. Medical To Feature Products at EASD 2010


TIRAT CARMEL, ISRAEL--(Sept. 20, 2010) - D. Medical Industries Ltd. (NASDAQ:DMED)(TASE:DMDC) ("D. Medical" or "Company"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, today announced that it is exhibiting at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD), September 20-24, 2010 in Stockholm, Sweden at booth No. B.01.42. D. Medical's exhibit, under the brand name Spring, will showcase the Company's ADI durable insulin pump and its Universal Detach Detect Infusion Sets.

"The EASD annual meeting brings together more than 16,000 attendees from over 100 countries," said Efri Argaman, D. Medical's Chief Executive. "We believe that increasing awareness and acceptance of our unique spring-based design through our participation in key industry events like this will go a long way towards achieving our goal of expanded adoption and use of our products in select European countries as we prepare to launch product sales in our five initial target markets - Mexico and the BRIC countries of Brazil, Russia, India and China - commencing in 2011."

About D. Medical

D. Medical is a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery. D. Medical has developed durable and semi-disposable insulin pumps, which continuously infuse insulin into a patient's body, using its proprietary spring-based delivery technology. D. Medical believes that its spring-based delivery mechanism is cost-effective compared to the motor and gear train mechanisms that drive competitive insulin pumps and also allows it to incorporate certain advantageous functions and design features in its insulin pumps. D. Medical has also developed an infusion set for insulin pumps and is focusing its research and development efforts on the development of next generation insulin pumps and a device that will combine a continuous glucose monitoring system and an insulin pump on the same patch. For more information, please visit http://www.dmedicalindustries.com (corporate) and www.springnow.com (healthcare professionals, patients and caregivers).

Forward-Looking Statements

This press release may contain forward-looking statements that involve risks and uncertainties. These statements include, inter alia, forecasts, goals, uncertainties and assumptions. The forward-looking statements are based on our current expectations and beliefs which are based on, among other things, our analysis of publicly available information and market research reports. All forward-looking statements are subject to certain risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. If one or more of these risks and/or uncertainties materialize, or if the underlying assumptions prove to be incorrect, our actual results, performance or achievements could differ materially from those expressed in, or implied by, any such forward-looking statements or results which are based upon such assumptions. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or of any of them will transpire or occur, what impact it will have on our results of the operations or financial condition. We do not undertake to update any forward-looking statements.



            

Contact Data